Greater Monroe Kennelgreatermonroekc.org/files/August_2014_Newsletter.pdfGreater Monroe Kennel...

Greater Monroe Kennel

August 2014, Volume 14, Issue 8

2014 Newsletter Editor:

Donna Otero

4975 Friendly Farms Road

Greensboro, NC 27406

[email protected]

GMKC by-laws state that the newsletter is to be distributed 2 weeks IN AD-VANCE OF THE GENERAL MEETING. Therefore, ALL articles and information for the newsletter need to be submitted by the TUESDAY that is 2 WEEKS FOLLOWING THE GENERAL MEET-ING. For the September 2014 news-letter, I will need all your information

by August 26, 2014.

Opinions expressed in this newsletter are those of the contributor and do not necessarily reflect the views of GMKC either as a group or individually.

Advice or helpful hints should never be taken as substitutes for personal veteri-nary counsel.

Contact and referral persons are in no way guaranteed by the GMKC

2014 Officers and Directors

President—John Schoeneman

Vice President—Martha Milligan

Secretary—Janet Broome

Treasurer— Gene Hains

Board of Directors

Beth Warren

Bobbe Jackson

Pat Ginocchio

Www.greatermonroekc.org

All Meetings are Now Held at the Hilltop Bistro

Next Meeting is Tuesday, August 12, 2014 at 7:00 p.m.

1602 E. Roosevelt Blvd.

Monroe, NC 28112

(704) 289-3733

We meet in the back room of the Bistro. In order to mini-

mize interruptions to the meeting, please plan to arrive by

6:00 p.m. if you are having dinner.

Board Meeting will follow after the regular meeting ad-

journs.

Click Box Below for most recent publication

Inside this edition:

AKCommunicates

General/Board Meeting Minutes July 2014 Page 2

Agility Match Announcement Page 5

Flyer Canine Reproduction and Whelping Seminar Page 6

Flyer Fun Scent Work Page 7

Karen’s Korner Page 11

C:/Users/Owner/Documents/AKCommunicates.docx

GMKC Paw Prints August 2014

www.greatermonroekc.org

GMKC MEETING MINUTES – JULY 8, 2014

Meeting called to order 6:51 p.m.

Motion to approve Minutes from last meeting. Vote to approve unanimous.

Secretary’s Report: No report this meeting.

President’s Report: No report this meeting.

Membership Secretary’s Report: Fourteen members present, six guests. Vote taken on Ruth Hoffman’s application for member-

ship, vote was unanimous. WELCOME RUTH TO GMKC. Chris and Gina Crawley’s application read before the membership, vote

will take place at the August meeting.

Members were present from the Salisbury Club, Sally, Sandy both teach obedience classes and Pat Harmon present who is active

on legislative affairs with NC Dog Federation and affairs occurring in the NC State Legislature.

Lisa Blackwell, from Concord, filled out an application at this meeting; it was read to the membership. Will be read again next

meeting.

Treasurer’s Report: Presented to the membership, Pat Ginocchio made motion to approve, second by Betty Montgomery. Vote

unanimous to accept.

Legislative Committee Report: Resolution coming up this Saturday to move the affairs of dog legislative matters in NC from the

Department of Agriculture to Public Safety. This moves the legislative affairs re: dog ownership, breeding regulations etc. from a

committee with an elected body to a body totally appointed by the Governor. GMKC and other AKC clubs are concerned about

this move, taking elected officials out of it and totally under the control of the Governor. Sec. Tommy Tucker is on this Dept. of

Agric. Committee, members need to contact Sen. Tucker to express our opinion about this move.

Pat Harmon has offered to post legislative information to Martha Milligan, Martha will post comments to the club.

Show Committee Report: Our August show is ready; we need volunteers to be present to work the Match on Wednesday, August

6, starting at 3 p.m. until the Match is finished. The club is willing to pay the first 14 members $50 each to sign up and work the

Match; they must work the full time from 3 p.m. until the Match is finished. Volunteers who work this schedule must show up

before 3 p.m. to be ready for the 3 p.m. start of the Match. Board motion will be voted on in July Board meeting to pay first 14

volunteers for beginning to finish Match ring work.

November Show: John and Bobbe are finishing up last judge assignment/contract.

Sign-up sheets are available from Martha for Breed Trophies for November. Martha will use candles with 1800’s breed

pictures on her candles (these require no copyright permission). If anyone wants a breed trophy different from those Martha will

supply, you must get the picture and mail it to Martha.

Group Trophies will be rosettes in shadow boxes. These were very nice last year and participants liked them.

Ginger’s contract needs to be signed for other clubs; John will take care of getting Ginger’s signature. Gene has signed

for GMKC; Cathy Rubin needs to sign the contract for Obedience/Rally.

Reports are that Fayetteville has stated they will be charging $28 and $25 for agility participants at their May 2015 show; agility

participants are very concerned since this is a price increase over GMKC charges. GMKC will remain $25 and $15 for agility partici-

pants, as per our past shows. Participants were concerned GMKC was increasing our charges, we aren’t.

Old Business: Gene is taking care of arranging a meeting with the attorney for the GMKC property.



New Business: No new business.

GMKC meeting adjourned at 7:20 p.m.

GMKC BOARD MEETING

Meeting called to order at 8:02 p.m. Board members present: John Schoeneman, Gene Hains, Bobbe Jackson, Pat Ginocchio, Ja-

net Broome, Beth Warren, and Martha Milligan.

Secretary’s Minutes: Approved, motion by Janet Broome, 2nd by Bobbe Jackson.

August Agility Show: Martha made a motion that the club pays first 14 volunteers who work the entire Match $50 per person to

work the Match on Wednesday, August 6, from start at 3 p.m. until the Match is finished. Number of paid volunteers who work

the Match will be limited to a maximum of 14 people working the Match. Volunteers will need to sign up to work the Match and

must work the entire Match until completion and sign out at the end of the Match. Beth Warren seconded the motion, vote

unanimous.

Gene will give $700 to Martha for paid volunteer expense; Martha will keep the list of volunteers paid for working the

match and give list to Gene to account for funds paid out. Volunteers must sign in on the list and sign out at the end of the

Match to qualify. Janet Broome will be responsible for the money and list at the end of the Wednesday Match.

President’s Report: The GMKC trailer where our turf is stored at the Concord Arena is leaking. The trailer is permanently parked

at the Arena. The Arena staff will empty the trailer of the turf and have a contractor determine where the leaks are occurring and

fix them. July 23 is when the Arena staff will empty the trailer and put the turf in the Arena so the contractor can check out the

roof and seams for leaks and repair them.

Turf pieces for sale: We have old pieces of turf the club wants to sell; there are 2 turf strip pieces approximately 15’W x 80-85’L.

The pieces have rounded corners. Pat Ginocchio will try to establish a reasonable price for these pieces and sell them at our Au-

gust Agility Show. Martha will tell Laurene we have these turf pieces for sale so perhaps Laurene can let exhibitors/participants

know prior to our show we have them for sale. The pieces are not padded.

Membership Secretary: Bobbe will email the membership list. We need a new membership roster and the new by-laws listed in

the roster. Janet Broome will send the by-laws to Bobbe; Martha will get the roster printed at Office Max in Matthews (unless

Martha and Bobbe find another location convenient and acceptable charge for printing).

Treasurer: Gene has checked with Bank of NC and Park Sterling for more reasonable banking fees for the club. Bank of America

has free checking for non-profit organizations, no charge for item # when keeping $10,000 in account. There was a motion from

Martha to move our checking business from BB&T to Bank of America, Beth Warren seconded, vote unanimous.

Apply for AKC Member Club Status: Martha made a motion for the club to request AKC Club Membership for GMKC, Pat second-

ed, vote unanimous.

General comments: Club made money from agility at the March Show. We didn’t have a profit from Obedience, not unexpected.

CDT made $6200 in agility & obedience at the March show; that was a good showing for them and more than made on their out-

door show.

More agility people are requesting indoor agility trials. GMKC has been on the cutting edge of indoor agility trials and are known

for our trials and location.

GMKC has settled accounts with Salisbury, now Salisbury owes GMKC money, Gene will check on exact amount.



November Show 2015: GMKC show will have agility, rally and obedience. The Corgi Club has approached us with the possibility

of having their conformation show at our November show. They would rent a ring from MBF. Board discussed where this ring

could be set up to avoid having to rent more space than we need for the agility, rally & obedience show, possibilities are renting

small side of Gold Hall or renting out grooming side of the Event Center to the Corgi Club for this event. We will discuss this pos-

sibility further; we aren’t making a commitment for the time being.

Board meeting adjourned 8:47 p.m.

______________________________________End of Meeting Reports________________________________________



Club Members Needed for Agility Match on

Wednesday, August 6, 2014

Volunteers are needed to be present to work the Match on Wednesday, Au-

gust 6, starting at 3 p.m. until the Match is finished. The club is willing to

pay the first 14 members $50 each to sign up and work the Match; they

must work the full time from 3 p.m. until the Match is finished. Volunteers

who work this schedule must show up before 3 p.m. to be ready for the 3

p.m. start of the Match. Contact Martha to sign up.

mailto:[email protected]?subject=Sign%20me%20up%20for%20the%20Wednesday%20Agility%20Match



Karen’s

Korner

Advasix Cancer Immunotherapy

Alternative Cancer Therapies

Adding Tavocept to Chemo

Bee Propolis Treats Infection

Better Seizure Management

Flea Product Comparison

Heartworm Product Comparison

For Dogs after Spinal Surgery

Kvax Cancer Vaccine

PharmAust Cancer Treatment

Researching a New Drug for Canine Distemper

Preparing Your Pet for Surgery

Alternative Cancer Therapies

I've included in the health section of the newsletter, mainstream cancer treatment programs. However,

there are a number of great alternative vets

that provide cancer treatments, and this is where I go when my dogs have had cancer. Treatments have

been very successful for various cancers from

my personal experience.

About CRVC - Cold River Veterinary Clinic 87 East Clarendon

Road, North Calrendon, VT 05759 Phone 803-747-4076

begin_of_the_skype_highlighting 803-747-

4076 FREE end_of_the_skype_highlighting email [email protected] Web Page www.crvetcenter.com

87 87 East Clarendon Road, North Clarendon, VT 05759 - Tel. (802) 747-4076

begin_of_the_skype_highlighting (802) 747-4076 FREE end_of_the_skype_highlighting

- [email protected] East Clar87 East Clarendon Road, North Clarendon, VT 05759 -

Tel. (802) 747-4076 begin_of_the_skype_highlighting (802) 747-

4076 FREE end_of_the_skype_highlighting - [email protected] Road, North

Clarendon, VT 05759 - Tel. (802) 747-4076 begin_of_the_skype_highlighting (802) 747-

4076 FREE end_of_the_skype_highlighting - [email protected]

Mission Statement:

Our purpose is to educate small animal owners and veterinarians about the nature and

causes of disease. We research and implement new and traditional therapies to treat

acute and chronic disorders in cats and dogs. Our goal is to bring about a long-term cure

for many diseases, using safe and effective therapies that promote good health.

Cold River Veterinary Center is an independent holistic veterinary practice with a special

interest in nutritional medicine. Our caseload includes complex medical cases where good

treatment options are hard to find.

Cancer Therapies

Dr. Kruesi has a special interest in safe natural therapies against cancer. We carry a wide

range of oral, topical, frozen extract and injectable options depending on the type and

stage of the tumor, and can special order custom formulations. Clients also receive infor-

mation on advancements in chemotherapy, radiation treatment and surgery whenever

they are indicated.

Since 1998 we have used these unique cell fractions of frozen tissue extracts to treat im-

mune deficiency disorders, infections, and cancer. Our treatments may include proteolytic

enzymes to facilitate autolysis or tumor decay. These products support normal physiology.

We treat patients that have round cell tumors, carcinomas, sarcomas and vaccine-induced

tumors using natural pharmaceuticals

letter - Cancer Important mai nl y because of the peopl e i n the conversati on.

Click to teach Gmail this conversation is not i mportant

Editor’s note: This is the first column in a two-part series on pet cancer in honor of Pet Cancer Awareness

Month, which is November.

Unfortunately, the “C” word invokes just as much fear for our four legged friends as it does for us. By now,

you know from my columns, dogs and cats are very similar to us; they live the same lifestyle, have similar

physiology and anatomy, and suffer similar diseases. Cancer is no exception.

According to a new Morris Animal Foundation (MAF) study, 1 in 4 dogs will die of cancer. If you are a gold-

en retriever the odds are a whopping 60 percent you will die of cancer. Past studies revealed that 11 per-

cent of visits to a veterinarian are for cancer-related issues.

I don’t know about you, but it makes me happy to see the MAF launch a $30 million initiative to cure ani-

mal cancer in the next 10-20 years (and if you are one of those who feel money spent on pets is wasted,

this research will be used to help cure human cancer).

Signs of cancer to watch for

One of the first indications your dog or cat has cancer are swellings or growths that continue to grow and

or change character, color etc. Other signs include: weight loss, decrease in appetite, difficulty urinating,

defecating or breathing, difficulty eating or swallowing, enlarged lymph nodes (glands), abnormal bleeding

or discharges from any body parts or openings, lameness or limping, weakness, lethargy or inability to ex-

ercise.

Just like in people, cancer is mainly a disease of middle-aged to older dogs and cats; however, pets of any

age can get cancer.

What to do if you suspect your pet has a tumor

If you suspect your pet has cancer you obviously need to schedule a visit with your veterinarian. They will

perform a good physical exam and then order some tests such as blood counts, blood chemistries, urinaly-

sis and X-rays or radiographs.

Often we do a very simple in-office procedure called a needle or aspiration biopsy and take a quick peek

under the microscope. Other times, a biopsy is indicated and sent to a board certified veterinary

pathologist.

A biopsy should be done if it will change the way a cancer is treated. For example, Mast Cell Tumors, a

common skin tumor, are malignant and require a very aggressive and wide surgical excision, whereas se-

baceous adenomas, another common skin tumor, are benign and require a very small surgical approach.

Information is king

Cancer should also be staged. Staging involves determining how extensive and widespread the cancer has

become.

Again, this will tell us how to treat the cancer and can save you and your pet needless surgeries, chemo-

therapies, expenses and suffering. Staging usually involves lymph node aspirates/biopsy, radiographs,

and/or an ultrasound. When dealing with cancer, information is king.

In part two, we’ll talk about some of the more common cancers and how to treat them.

In the meantime, visit www.morrisanimalfoundation.org or www.acfoundation.org and make a contribu-

tion to the canine cancer campaign!

Stephen Sheldon, DVM, a member of the Veterinary Cancer Society, practices at Gypsum Animal Hospital.

He welcomes your questions and can be reached at 970-524-DOGS or www.gypsumah.com or

[email protected]. Return to Karen’s Korner

Pet Talk column: What to do when your

pet has cancer, part two

Pet Talk: What to do if your dog has can-

cer

Editor’s note: This is the second column in a two-part series. Visit www.vaildaily.com to read the first in-

stallment.

In this past week’s article we discussed some signs and symptoms of cancer and how we diagnose them.

Now, let’s move on to some of the more common cancers and how to treat them.

Basically you have three choices for therapy: Cut it out (surgery), poison it out (chemotherapy) or burn it

out (radiation therapy). Without being flippant, that is exactly what we are going to do. Dr. Greg Ogilve,

Colorado State University’s animal cancer guru, advocates surgery as the first line of treatment and says:

“when in doubt, cut it out” and “your best deal is cold blue steel.”

Successful Treatments

For some cancers, surgery is all that is needed; others require chemotherapy to prevent spread, called me-

tastasis, and still others require radiation therapy. Sometime a combo of chemo and radiation is used.

Often times a tumor cannot be removed or it is too large to remove so we try chemo or radiation to shrink

the tumor to a more manageable size, and then remove it.

Other cancers need chemo to control them, for example lymphoma (cancer of the lymph nodes) or leuke-

mia (cancer of the white blood cells) cannot be treated surgically. Staging, or determining how widespread

the cancer is, will tell us what type of chemo to use and for how long.

Yes, chemo is a scary word but pets tolerate it a lot better than we do. I would say more than 95 percent of

the owners who have had me do chemo on their pets would do it again if needed. Dogs rarely loose their

hair (except maybe whiskers) and usually only have a day or two of nausea between cycles.

Phases of Chemo

There are two phases to chemo: the induction phase, which is rigorous and done weekly until the cancer is

in remission; then a maintenance phase is started where a round of chemo is given every 3 to 4 weeks un-

til all the cancer is gone. Chemo routines, called “protocols,” are changing all the time; the line between

where induction ends and maintenance begins is a hot topic today.

Radiation therapy is done much less in my experience because it must be done very frequently; often up to

3 times a week. For us that means going to Denver (and as I write this, I-70 is closed eastbound).

Common Cancers

Let’s move on to some common cancers. Breast cancer in female dogs is very common and a good example

where surgery alone can be curative. This cancer is almost 100 percent preventable by spaying your female

dog before her first heat cycle. If the cancer is malignant or advanced, then radiation is the preferred

method to prevent spreading; however, I have used chemo successfully. Mast cell tumors are a common

dog skin tumor and need to have a very wide and deep surgical excision, therefore a pre-op needle biopsy

should be done. This tumor should be sent of to a pathologist to grade, from 1 to 3, to tell us the degree of

malignancy as this will dictate what or even if chemo is needed. Other common canine cancers are lym-

phoma, bone cancer, intestinal cancer and oral cancers.

Cats are also prone to cancer. Breast cancer is much more serious in cats than in dogs as almost all are ma-

lignant, whereas only half are malignant in dogs. In one large study of 439 cats, only 8 percent had benign

tumors (meaning 92 percent were malignant). Early spaying is recommended but we can’t say for certain if

it prevents breast cancer in cats. Skin tumors are also more malignant in cats than dogs so if you see

bumps on your cats, get them checked out. Intestinal cancer is also more common in cats than dogs.

Treating cancer can be expensive but it is rewarding for both veterinarians, pet owners and life extending

for pets. Just ask my last case, Maya, who can be seen walking around Eagle!

Veterinarian Stephen Sheldon, a member of The Veterinary Cancer Society, practices at Gypsum Animal

Hospital. He welcomes your questions and can be reached at 970-524-DOGS or www.gypsumah.com and

[email protected].

Return to Karen’s Korner

Dr. Richard Palmquist

Chief of Integrative Health Services at Centinela Animal Hospital, Inglewood California

Researching a New Drug for Canine Dis-temper

Successful new drugs are rare. Most ideas for new drugs end up being just that: ideas.

They either never make it out of the test tube, fail preliminary testing, or prove to be

no better than other available therapies. Some may look promising only to be found to

cause significant adverse effects. A significant barrier to development involves the

profit potential or size of the disease market for a new drug. After all, if there are not

enough cases of a disease to make it possible to recoup the expense of approval, many

good drugs just languish in the patent office. The problem is even larger for natural

therapies as the profit potential is much smaller.

Integrative medicine investigates the use of nutrition, conventional therapies and oth-

er forms of healing that have some scientific basis in support of their use. This type of

practice involves doing a lot of research, both of traditional literature as well as read-

ing publications far off the beaten path. Integrative doctors even read anthropology

literature as we seek knowledge from indigenous cultures that often have a tight knit

connection to nature and the resources she provides.

Canine distemper is a killer disease that spreads by simply breathing or touching ma-

terials contaminated by the virus. The virus infects all epithelial tissues and is shed in

saliva, mucus, urine and stool. It hides in the environment quietly awaiting a suscepti-

ble puppy and then strikes with signs of a mild cold. The runny nose and cough pro-

gresses until the dog is ravaged by pneumonia and encephalitis. Many dogs die having

terrible seizures, and the dogs that are lucky enough to survive are often disabled for

life with brain damage, ongoing seizures, nervous tics and skin problems.

Veterinarians are lucky to have effective vaccinations against canine distemper, and

the vaccinations work well. Many puppies are protected for life by a simple series of

two vaccinations. Because of this many veterinarians and owners never see the dis-

ease. It does not get big headlines or have a private foundation with celebrities raising

money for a solution, but canine distemper is a killer.

This disease spreads easily in areas with lower education, pet overpopulation and re-

duced use of vaccines. It is a significant problem in inner cities, animal shelters and

pet rescue groups. Its gradual onset allows it to spread rapidly through populations

and it is heart breaking to watch dogs suffer death or disability from the disease.

Based on the textbooks and poor outcomes anticipated, many veterinarians simply eu-

thanize these dogs. Sadly, practitioners like me that work with rescue groups and ani-

mal shelters often see these sort of cases, and sometimes they arrive at our clinic too

late to save them.

While vaccination is the best policy, sometimes the disease strikes before a dog re-

ceives the vaccination. Animal shelter workers know the devastating toll suffered as

they watch newly admitted dogs succumb. In such cases distemper does not need to be

a death sentence for a dog. A combination of homeopathic, nutritional, herbal and

conventional drugs and support often does the trick. The course of treatment is long

and arduous, though. Staying up all night with a puppy crying from encephalitis is ex-

hausting, especially when there is no guarantee of survival or total recovery.

There may be new hope for this disease. Recently, I have come across an experimental

drug from a new company in Florida. Holistic doctors have used this medication for

other viral infections with interesting results and now this drug that originates from a

natural substance is working its way through the FDA application and approval pro-

cess, which can take years. This drug, currently code-named PVX, is an anti-viral of

natural origin, and veterinarians who are using it have seen many cases where it

worked.

Once such case was a rescued Chow Chow named Sheena that was adopted in June of

this year. Her new owner loved Sheena, but she soon begin showing signs of severe ill-

ness including fever, ocular and nasal discharges and severe twitching of her front

paws to the degree that she could not walk. After failure of conventional therapies in-

cluding support, antibiotics, fluids and anticonvulsants, she was referred to me

through a rescue group I had worked with before. His regular veterinarian was very

supportive of that process because she had nothing else to offer and wanted to see

Sheena have a chance.

As I looked at Sheena, the case really didn't look good. After explaining the serious na-

ture of this infection, we confirmed it with a blood test that detects virus DNA. We ad-

vised of the experimental, humane access FDA trial and we began therapy. Darren,

Sheena's new owner, was able to perform most of her treatment at home. He returned

weekly to our office. We saw fast results as Sheena started eating again and her other

symptoms lessened. Since most cases like this would take weeks to show improve-

ment, we were all ecstatic.

Over the 4th of July weekend we had a scare. Sheena stopped eating and became very

lethargic. We intervened quickly with additional doses of PVX at twice the normal dos-

age. Darren was great in this process, he gave Sheena her medicine daily as required,

and kept in touch with me regularly by email, phone and regular visits to my hospital

over the course of the six weeks or so of treatment.

The story does have a happy ending. Sheena survived and is with us today. She still

demonstrates a little bit of involuntary movement in her left front paw, but it does not

affect her quality of life.

This was not a simple therapy. It took full cooperation of Sheena's guardian, and regu-

lar visits to my clinic. Sheena's seizures were controlled almost immediately with ho-

meopathic medicine (Belladonna Homaccord). Her ravaged body responded to nutri-

tional care that supported her organs and immune system and helped drain the toxins

away before they overwhelmed her. It took love enough to ask for more options and

persistence to check out things on the Internet, do research in rare literature and ded-

ication to drive Sheena two hours to our clinic. It also took a pioneering spirit to take

chances and work with others regardless of the outcome and odds against us.

This drug is still at a very early stage and this year participating veterinarians have

treated over 50 cases with an incredible 80 percent success rate. It's possible in the fu-

ture the process might be simpler and cheaper, but the bottom line is this drug and

other rare therapies may become a new tool in our integrative arsenal against a dis-

ease in our canine friends which has often been a death sentence in the past. And who

knows what other conditions may benefit once that research is done.


PharmAust's cancer drug approved for clinical trial in canine cancer treatment

Thursday, February 20, 2014

PharmAust, in conjunction with Vet Oncology Consultants at the Animal Referral Hospital in Homebush, New South Wales,

will now conduct a clinical trial to test the anticancer drug PPL-1 in a small number of pet dogs

PharmAust Limited (ASX: PAA) has received approval from the Director General’s Animal Care and Ethics Committee

to commence the evaluation of its PPL-1 drug in the treatment of canine cancers.

PharmAust, in conjunction with Vet Oncology Consultants at the Animal Referral Hospital in Homebush, New South

Wales, will now conduct a clinical trial to test the anticancer drug PPL-1 in a small number of pet dogs.

The trial will test the safety and efficacy for treating superficial soft tissue sarcomas, chemotherapy resistant lympho-

mas, and metastatic melanomas.

All pet dogs admitted to the trial will be treated with the drug by their owners at their homes.

To determine the safest and most effective dose, the trial design will incorporate incremental increases in drug quanti-

ty to different groups of dogs.

Tumour size will be measured before and after treatment using callipers, CT scan or radiographic imaging.

The U.S. pet market is substantial with over 75 million pet dogs, and around 60% of dogs over the age of 6 develop

some form of cancer, according to Petplan Pet Insurance’s claims.

U.S. pet cancer therapies are estimated at $550 million, with a price point of around $1,500 per treatment.

Sha

HEARTWORM PRODUCT COMPARISON

For

Dogs

or

Heartworm

Preventing

Ingredient

Other Ingredients

for Control of

Other Parasites

Other Parasites Con-

trolled

Mode of

Applica-

tion

Youngest

Age to Start

Using

Heartgard Dogs Ivermectin None None oral 6 weeks

Heartgard

Plus

Iverhart

Plus

Iverhart

Max

Triheart

Plus

Pet Trust

Plus

Dogs Ivermectin

pyrantel

pamoate

Iverhart Max also

has praziquantel

hookworms, round-

worms

Iverhart Max also

covers tapeworms

oral 6 weeks

Heartgard Cats Ivermectin none hookworms oral 6 weeks

Interceptor Dogs

and

Cats

Milbemycin

Oxime bone

hookworms, round-

worms, whipworms oral

4 weeks

for puppies

6 weeks

Sentinel

Sentinel

Spectrum Dogs

Milbemycin

Oxime

Lufenuron

Sentinel Spec-

trum also has

praziquantel

hookworms, round-

worms, whipworms,

sterilizes fleas

Sentinel Spectrum

also covers tape-

worms

oral 4 weeks

Revolution

Dogs

and

Cats

Selamectin None

For dogs: fleas,

ticks, ear mites, sar-

coptic mange mites

For Cats: fleas, ear

mites, hookworms,

topical

6 weeks

for puppies

8 weeks

for kittens

Advantage

Multi Dogs

and

Cats

Moxidectin Imidocloprid

For dogs: fleas,

hookworms, round-

worms, whipworms

For Cats: fleas, ear

mites, hookworms,

roundworms

topical

7 weeks

for puppies

9 weeks

for kittens

Proheart6

Dogs Moxidectin None hookworms injectable

6 months

(and no old-

er than 7

Trifexis

Dogs Milbemycin

Oxime Spinosad

fleas, hookworms,

roundworms, whip-

worms

Oral

8 weeks

How

Often

Used

Approved for

Pregnancy and

Lactation?

Water

-

proof

?

Safe to Give to

Heartworm

Positive Ani-

mal?

Manufactur-

er Website

LD50

Heartgard

for Dogs

month-

ly yes yes yes Heartgard

10 mg/kg in rats orally according to MSDS

sheet for Parade Equine Gel

Heartgard

Plus

Iverhart

Plus

Triheart

Plus

Pet Trust

Plus

month-

ly yes yes yes

Heartgard

Plus

Iverhart

Plus

Triheart Plus

PetTrustPlus

10 mg/kg in rats orally for ivermectin; >690

mg/kg in dogs orally for Pyrantel Pamoate ac-

cording to The Elephant Formulary by Mikota

and Plumb

Heartgard

for Cats

month-

ly yes yes yes Heartgard 10 mg/kg in rats orally

Intercep-

tor month-

ly yes yes

In most cases

yes but if mi-

crofilariae

numbers are

high then no

Interceptor

LD50 information unavailable

Symptoms of tremors and incoordination re-

sult at 19 times recommended dose

Sentinel

Sentinel

Spectrum month-

ly yes yes

In most cases

yes but if mi-

crofilariae

numbers are

high then no

Sentinel

LD50 information unavailable

Symptoms of tremors and incoordination re-

sult at 19 times recommended dose

Revolution month-

ly yes yes yes Revolution >1600 mg/kg in the rat orally

Advantage

Multi month-

ly no no yes

Advantage

Multi

Moxidectin: 106 mg/kg orally;

Imidocloprid: 450 mg/kg in the rat orally

Proheart6

every 6

months yes yes

No, in fact

owner must

agree to

pre-treatment

labwork in-

cluding heart-

worm testing

Proheart6 263 mg/kg in the rat when given by injection

(the dose used therapeutically is 0.17mg/kg)

Trifexis

month-

ly

Manufactuer

cautions use,

says to discuss

with your vet-

erinarian

yes

In most cases

yes but if mi-

crofilariae

numbers are

high then no

Trifexis

Milbemycin Oxime: LD50 information unavaila-

ble Spinosad: >3,000 mg/kg in rats; >2,000

mg/kg in rabbits (translates to over 30 times

recommended dose)

Table 1 Flea Killing Ingre-

dient

Flea Sterilizing Or

Additional Ingredi-

ents

For Dogs

or Cats

Youngest Age or

Size

Approved for Use

Waterproof or

Water Resistant?

Comfortis,

AcuGuard* Spinosad none dog

14 weeks; at least

5 lbs waterproof

Trifexis Spinosad Milbemycin (for add’l parasites)

dog 8 weeks; at least 5 lbs

waterproof

Assurity Spinetoram none cat 8 weeks water resistant

Vectra 3D,

SimpleGuard 3*,

FirstShield Trio*

Dinotefuran &

Permethrin

Pyriproxifen (flea

sterilizer) dog

7 weeks;

at least 2.5 lbs water resistant

Vectra for Cats,

SimpleGuard for

Cats*, FirstShield

for Cats*

Dinotefuran Pyriproxifen (flea

sterilizer) cat 8 weeks water resistant

Revolution Selamectin none dog or cat 6 weeks puppies

8 weeks kittens waterproof

Advantage II Imidacloprid Pyriproxifen (flea

sterilizer) dog or cat

7 weeks puppies


K9Advantix II Imidacloprid &

Permethrin

Pyriproxifen (flea

sterilizer) dog 7 weeks waterproof

Advantage Multi

also calledAdvocate Imidacloprid

Moxidectin

(for additional para-

sites)

dog or cat 7 weeks puppies


Frontline

Fiproguard, PetAr-

mor, EasySpot

(cats)

Parastar (dogs)

Fipronil none dog or cat 8 weeks waterproof

Frontline Plus,

Fiproguard Plus,

PetArmor Plus

Fipronil Methoprene (flea

sterilizer) dog or cat 8 weeks waterproof

Program none Lufenuron(flea ster-ilizer)

dog or cat 4 weeks waterproof

Sentinel none

Lufenuron(flea ster-

ilizer) &

Milbemycin (for

add’l parasites)

dog 4 weeks; at least 2

lbs waterproof

Capstar Nitenpyram none dog or cat 4 weeks; at least 2 lbs

waterproof

FLEA PRODUCT COMPARISON

Table 2

Approved for Preg-nancy and Lactation (nursing)

How Long Until Maximum Effect Against Fleas Is Reached?

Other Parasites Killed, Controlled or Repelled

How Often Applied or Administered?

Comfortis, AcuGuard*

Manufacturer recom-mends against use but not specifically labeled against

100% fleas dead in 4 hours

none monthly

Trifexis

Manufacturer recom-mends against use but not specifically labeled against

100% fleas dead in 4 hours

hookworms,

roundworms,

whipworms&

heartworms

monthly

Assurity Manufacturer recom-mends consulting with veterinarian first

98 - 100% fleas dead in 12 hours

none monthly

Vectra 3D, SimpleGuard 3*, FirstShield Trio*

No 96% of fleas dead in 6 hours

kills ticks; repels flies and mosquitos

monthly

Vectra for Cats, SimpleGuard for Cats*, FirstShield for Cats*


none monthly

Revolution Yes 42 hours to zero fleas

dogs: ticks, ear mites,

sarcoptic mange mites&

heartworm larvae cats: hookworms, roundworms, ear mites & heartworm larvae

monthly

Advantage II Manufacturer recom-mends consulting with veterinarian first

98% of pre-existing fleas dead in 12 hours; then new fleas in 2 hours

none monthly

K9Advantix II No 98% of fleas dead in 12 hours

kills ticks; repels flies and mosquitos

monthly

Advantage Multi also calledAdvocate


dogs: whipworms, hookworms, roundworms &

http://www.veterinarypartner.com/Content.plx?P=A&A=476&S=0&EVetID=0







Advaxis Cancer Immunotherapy Featured on CNN

PRINCETON, Mar 03, 2014 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. ADXS -4.05% , a biotechnology company

developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immuno-

therapy designed to treat women with breast cancer, was featured on CNN in a segment focused on its success in

treating dogs with osteosarcoma (bone cancer). The segment includes an interview with Dr. Nicola Mason, Assistant

Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, who is the

principle investigator of the featured study, funded by Advaxis, to evaluate ADXS-cHER2 in companion dogs with

bone cancer.

The story can be viewed here:http://www.cnn.com/video/data/2.0/video/health/2014/02/27/hm-dogs-and-

vaccines.cnn.html

In the CNN interview, Dr. Mason states that the Advaxis immunotherapy is safe and effective in treating canine oste-

osarcoma, with treated pets living significantly longer than pets that do not receive treatment. The immunotherapy

was originally developed to target the Her2-Neu gene, which is overexpressed in some breast cancers and in some

cases of pediatric osteosarcoma. Dr. Mason identified the potential veterinary application and designed this trial to

confirm its usefulness in treating animals.

"We are thrilled with the tremendous results that Dr. Mason is seeing in treating companion dogs with osteosar-

coma," commented Daniel J. O'Connor, Chief Executive Officer of Advaxis. "The use of our immunotherapy to ad-

dress canine osteosarcoma has created significant awareness about the potential of Advaxis's cancer immunothera-

pies to treat human cancers. We are looking forward to advancing the development of ADXS-cHER2 into Phase 1 clin-

ical trials for breast cancer this year. In addition, we will evaluate the potential to develop ADXS-cHER2 for pediatric

osteosarcoma."

About ADXS-cHER2

ADXS-cHER2 is an Lm-LLO immunotherapy for HER2 overexpressing cancers (such as breast, gastric, and other can-

cers in humans and for osteosarcoma in canines). ADXS-cHER2 secretes the cHER2 antigen, fused to LLO, directly in-

side the APC that are capable of driving a cellular immune response to HER2 overexpressing cells. In preclinical analy-

sis, localized effect is the inhibition of the Treg and MDSC cells that we believe may promote immunologic tolerance

of the HER2 overexpressing cancer cells of the tumor.

About Canine Osteosarcoma

Osteosarcoma is the most common primary bone tumor in dogs, accounting for roughly 85% of tumors on the canine

skeleton. Approximately 8,000-10,000 dogs a year (predominantly middle to older-aged dogs and larger breeds) are

diagnosed with osteosarcoma in the United States. This cancer initially presents as lameness and, oftentimes, visible

swelling on the leg. Current standard of care treatment is amputation immediately after diagnosis, followed by

chemotherapy and sometimes radiation. Invariably, the cancer metastasizes to the lungs, eventually leading to

death.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.

Advaxis's immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the

immune system to selectively target cancer cells while reducing tumor defenses.

ADXS-HPV, Advaxis's lead immunotherapy for the treatment of HPV-associated cancers, has demonstrated improved

survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is

now planning the registrational program for ADXS-HPV. ADXS-HPV is also being evaluated in other HPV-associated

cancers including a Phase 2 in advanced cervical cancer, a Phase 1/2 in head and neck cancer, and a Phase 1/2 in anal

cancer. ADXS-HPV has orphan drug status for both anal and head and neck cancers. As part of its global commerciali-

zation strategy to enter into regional licensing deals with other market dominant biopharmaceutical companies in

territories where there is a high prevalence of HPV-associated cancers, Advaxis has granted exclusive licenses for the

development and commercialization of ADXS-HPV in Asia and India.

ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing cancers (such as breast, gastric, esopha-

geal, and other cancers in humans and for osteosarcoma in canines). Advaxis's lead animal-health immunotherapy,

ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1 trial in canine osteosarcoma. These data pro-

vide the rationale to advance this same immunotherapy into a Phase 1 clinical trial in women with HER2-positive

breast cancer. The Company is preparing an IND submission for ADXS-cHER2 in breast cancer in 2014.

Advaxis has created more than 20 distinct immunotherapies based on its platform, either directly or through strate-

gic collaborations with recognized cancer centers of excellence. We have clinical research collaborations with the

University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of

Medicine at Mount Sinai, and others.

For more information please visit www.advaxis.com or connect with us on

-- Facebook: https://www.facebook.com/advaxisinc

-- Twitter: https://twitter.com/Advaxis

-- LinkedIn: http://www.linkedin.com/company/advaxis-inc .

-- Google+:https://plus.google.com/b/115126287957745987074/115126287957745987074/posts

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's

ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary

immunotherapy, ADXS-HPV; whether Advaxis immunotherapies can redirect the powerful immune response all hu-

man beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks,

including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on

Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes

no obligation to publicly release the result of any revision to these forward-looking statements, which may be made

to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, ex-

cept as required by law. You are cautioned not to place undue reliance on any forward-looking statements.


Regeneus: Study highlights efficacy and safety of Kvax cancer vaccine

Thursday, March 06, 2014 by Proactive Investors

Regeneus highlights study that shows efficacy and safety of Kvax cancer vaccine

Regenerative medicine company Regeneus (ASX: RGS) has received support for the efficacy and safety of its licensed

Kvax cancer vaccine with a paper showing it led to remission rates of 30%-60% in rats with brain tumour.

Kvax uses the removal of a tumour or biopsy from the patient as source material to produce a personalised vaccine

that stimulates the patient’s immune system to see the cancer cells as foreign.

Regeneus has an exclusive worldwide licence for commercialisation of the technology for veterinary applications and

an option over all human applications.

The paper “Streptavidin: A novel immunostimulant for the selection and delivery of autologous and syngeneic tumor

vaccines”, which was published in the peer-reviewed journal Cancer Immunology Research, describes experimental

work in a pre-clinical rat glioma (brain tumour) model.

Besides showing that Kvax led to remission rates of 30%-60%, upon challenge these animals did not get the disease,

which indicates acquired immunity.

The paper also described the treatment of 25 dogs that had a range of advanced cancers.

These companion animals presented at veterinary clinics in Sydney with cancer types ranging from melanoma to bone

cancer. Dr Chris Weir, who developed the technology with Professor Ross Davey, produced personalised vaccines for

the vets to administer to the dogs.

The study in dogs demonstrated that there were no safety issues with the vaccine and that the dogs often survived

longer than expected indicating that the vaccine can slow tumour growth and recurrence.

“The results from the work in rats is a major breakthrough,” said Dr Weir from Bill Walsh Translational Cancer Re-

search Laboratory.

“The 9L glioma model is extremely aggressive, and achieving the level of remission and immunity that we did, using a

vaccine derived from tumours is significant and unique.”

Regeneus Veterinary Business Unit head Duncan Thomson said the work in dogs suggests that the vaccine is effective

in a wide range of tumour types, making it a significant commercial opportunity.

The company had in November 2013 received the green light to commercialise the canine vaccine in the U.S. through

the Centre for Veterinary Biologics at the U.S. Department of Agriculture.

It will now focus on setting up a vaccine manufacturing site in the U.S. and beginning a marketing trial with key opinion

leaders in the US.

According to the US National Canine Cancer Foundation, cancer accounts for almost half of the deaths of pets over 10

years of age, which is roughly the same rate as humans.

Analysis

With cancer accounting for almost half of the deaths of pets over 10 years of age, the paper provides Regeneus with

further support to the safety and efficacy of its Kvax cancer vaccine.

That the vaccine led to remission rates of 30%-60% for rats in the trial in light of the extremely aggressive 9L glioma

brain tumour in rats is also encouraging.

With the focus now on setting up a manufacturing site, Regeneus is now well on its way towards commercialising the

vaccine.


adjunct drugs do not improve neurologic function

FOR DOgS AFTER SPINAL DISEASE SURgERY

By Christine Carmine, DVM

Herniated intervertebral discs are common in certain breeds of dogs, such as Dachshunds, Shih Tzus and Pekingese. In the most severe cases, where dogs

are paralyzed and have no feeling in their limbs, surgery

to relieve pressure from the herniated disc offers the best chance of recovery. Veterinarians will sometimes administer high doses of steroids before and

after surgery in the hopes that this will improve the outcome. The use of steroids in this capacity has been the topic of some debate, since steroids have

serious potential side effects, including gastrointestinal ulcers and bleeding.

Funded by Morris Animal Foundation, researchers from North Carolina State University evaluated two adjunct medical therapies to determine how they

would affect the outcomes of dogs that underwent surgery for acute spinal cord injury. The two medical therapies evaluated included a commonly used

steroid, methylprednisolone sodium succinate, and a new

class of drug called fusogens, specifically polyethylene glycol fusogen. Results indicated that neither therapy improved neurologic function after surgery

in dogs with severe spinal cord injury. While it was disappointing that neither drug improved outcomes, this is important information for veterinarians to

know when

providing postsurgical treatment.


Adding Tavocept to chemotherapy reduces

infusion time By WINONA BURGESS, DVM, CPA, MBA

RESEARCH SPOTLIGHT

Transitional cell carcinoma (TCC) is the most common malignancy affecting the urinary bladder in dogs. The disease most often affects the trigone region of the

bladder, making urinary tract obstruction likely and complete surgical excision difficult at best.

By the time TCC is diagnosed in a dog, it is usually invasive and advanced to the point that local therapies, which are quite successful in people, are often ineffective.

Furthermore, even if local disease control can be achieved, the high metastatic rate (about 50 percent) of TCC in dogs necessitates systemic therapy in order to

prolong survival.

Various chemotherapy protocols have been evaluated for treatment of TCC of the bladder in dogs. Although a combination of cisplatin and piroxicam has provided

the best response rates to date (more than 71 percent measurable responses), drug-induced nephrotoxicity is a frequent and dose-limiting complication.

Funded by Morris Animal Foundation, Carolyn Henry, DVM, and her team at the University of Missouri recently completed a clinical trial to test

the ability of a new experimental drug, Tavocept, to reduce the chemotherapy-induced side effects of cisplatin and piroxicam when treating dogs with bladder

cancer. In human patients, Tavocept has been shown to prevent or mitigate common and serious toxicities associated with cisplatin chemotherapy.

Although the researchers determined that the combination of cisplatin, tavocept and piroxicam wasn’t superior to current protocols in terms of bladder-tumor

response or kidney toxicity, they did discover that the addition of Tavocept to

the protocol significantly decreased the time to administer cisplatin. Saline diuresis was reduced from 61⁄2 hours to only 90 minutes.

The results of this study demonstrated that Tavocept can facilitate a more rapid cisplatin- infusion protocol, thus making cisplatin administration more practical in a

private clinic setting. With this information, the researchers hope to expand the use of cisplatin against additional tumor types and at higher and more effective

doses.


Extended-release tablet

may provide better

seizure management By Winona Burgess, DvM, CPa, MBa

ReSeaRCh SpotlIght

Dr. Boothe’s Foundation-funded study at Auburn University may help German Shepherds and other breeds that have a genetic predisposition to epilepsy.

In a Morris Animal Foundation–funded clinical trial, Dawn Merton Boothe, DVM, MS, PhD, and her research team at Auburn University tested an extended-release

anticonvulsant drug for use in the control of epilepsy in dogs. They learned that extended-release administration has great potential.

Previous studies have shown that levetiracetam (commercially known as Keppra) is well tolerated by dogs, even at concentrations that exceed the maximum thera-

peutic range for humans. However, the half-life of Keppra in dogs is very short (usually less than two hours), so drug levels are often subtherapeutic or not detecta-

ble at the end of an eight-hour dosing interval.

To find a better treatment option, Dr. Boothe and her team studied the drug levels of a new extended-release levetiracetam that was recently approved for use in

humans. They discovered

that a single oral dose of the extended-release levetiracetam (Keppra XR) safely maintained therapeutic blood concentrations in dogs for at least 12 hours. In addi-

tion, they found that the bioavailability of the drug was much higher in fasted dogs than in those that were fed.

The research team noted that the only limitation of the new extended-release version of levetiracetam was the tablet size. Because Keppra XR is only available in

750 mg tablets, this could potentially limit its use to dogs weighing 15 kg or more.

Dr. Boothe and her team recommend frequent monitoring when establishing a proper dosing regimen for each patient. However, once this regimen has been estab-

lished, dogs receiving Keppra don’t require any more frequent monitoring than those receiving other anticonvulsant drugs.


Natural Pet Care C O L D R I VE R VE T E R I NA RY C E N T E R

Bee Propolis treats infections

Propolis is made from the resin of tree buds, collected by honeybees and processed into a yellow-brown waxy substance that is used

to cement or weatherproof parts of the hive. Bees also use propolis to embalm insects that invade the hive. It has a long history of

traditional use against infections and ulcers. The composition of propolis may vary depending on the region where it is collected but

its antibacterial activity is generally similar from all sources.

Bee propolis can be used in the treatment of bacteria, yeast, fungal, and certain amoebic infections. For example propolis treatment

administered to mice inoculated with Giardia lamblia showed a significant decrease in infection and was superior to a 6-day treatment

with Metronidazole, the standard drug therapy. At 12 days the 2 medicines had equivalent efficacy against Giardia infection.1

Propolis is effective as a topical treatment against Candida yeast and Trichosporon fungi that cause nailbed infections

(onychomycosis).2 Patients with superficial my- cosis (yeast, fungal or ‘ringworm’ infections) caused by Candida albicans, Tricho-

sporon species and Rhodotorula species were susceptible to low concentrations of bee propolis.3 For patients that have drug-resistant

infections or should not take anti- fungal medications due to preexisting liver or adrenal disease, bee propolis offers an effective al-

ternative with little adverse side effects.

Alcohol (ethanol) extracts of bee propolis have shown high antibacterial activity against gram positive cocci such as Staphylococcus

aureus4, a common pathogen of glands and a variety of oral bacteria including Peptostreptococcus, Actinomyces, Prevotella and Por-

phyromonas gingivalis.5

At CRVC bee propolis is used to treat gram-positive bacterial infections of ears, skin, oral cavity, and intestines. It can be used in

mixed infections when combined with other natural antibacterial medicines such as olive leaf extract, or herbal formulas that in-

clude Goldenseal. For information on obtaining a sterile swab for bacteria culture see www.crvetcenter.com/earculture.htm.

Bee Propolis treats infections (continued)

Bee propolis from the Anatolian region in Turkey inhibited the oral bacteria Streptococ- cus mutans, Staphylococcus aureus, Staph-

ylococcus epidermidis, and Enterobacter. The authors concluded that propolis can prevent dental caries since it demonstrated signifi

- cant antimicrobial activity against common microorganisms involved in oral disease.6

Propolis has been less effective against gram-negative bacteria such as Salmonella typhimurium, Pseudomonas aeruginosa, and E.

coli.6,7,8 Clostridium, Bacteroides, and Propionibacterium were intermediate in susceptibility to propolis in vitro.8 Like other antimi-

crobials, propolis should be dosed based on bacteria culture with the gram- positive bacteria being the most susceptible at the lowest

concentrations.

Helicobacter pylori is a primitive spiral-shaped bacteria that has been found in the mucus wall of patients with stomach ulcers. It

has been implicated in chronic vomiting syndromes in dogs and is thought to perpetuate peptic ulcers even if the bacterium was not

the primary cause. In a recent study a 30% ethanol extract of Propolis had strong antibacterial activity against Helicobacter pylori

in vitro8,9, supporting one of the traditional uses for this natural medicine.

Recent publicity about Methicillin-resistant Staphylococcus aureus (MRSA) should prompt new investigations into propolis to treat

multi-drug resistant skin infections. As these studies show, propolis also is indicated for the treatment of intestinal infections caused

by Giardia, periodontal infections, gingivitis, intestinal bacterial pathogens, and Candida yeast. There is no synthetic drug that car-

ries the same efficacy and safety against such a wide variety of pathogens. Furthermore, few antibacterial drugs could match the cost

effectiveness of propolis, the ultimate in environmentally friendly medicine.

Cold River Veterinary Center 87 East Clarendon Road North Clarendon, VT 05759 Nutritional Medicine at www.crvetcenter.com


Bone fractures, torn ligaments, a broken tooth or other calamities happen that require

surgery. Hospital-acquired infections are a risk with most procedures so it pays to be pro-

active in minimizing the bacterial load prior to surgery. Here are some tips gleaned

from Dr. Kruesi's 15 years in holistic veterinary practice.

A great resource for anyone dealing with Cushings Disease in dogs is this

Group:

http://pets.groups.yahoo.com/group/CanineCushings-AutoimmuneCare

[QUOTE

(OUR MISSION)

"CCAC is an international community of lay people and veterinarians

interested in hyperadrenocorticism, canine Cushing's syndrome, steroid

hormone aberrations and associated disorders (e.g. liver disease,

pancreatitis, diabetes, IBD, kidney disease, UTI, bladder stones,

incontinence, heart disease, hypertension, thromboembolism, hypothyroidism,

myotonia, arthritis, osteoporosis, calcinosis cutis, SARDS, cancer,

pituitary/adrenal tumors, seizures, Alopecia X, hyperestrinism, autoimmune

polyglandular syndromes, iatrogenic hypoadrenocorticism/Addison's,

Addisonian crisis).

Preparing your pet for surgery

We offer a wide range of educational resources, including the support and

experiences of other pet owners, the expertise of veterinarians, a guest

speaker program, tools to help you monitor your pet's health and a

full-featured website. We value critical thinking and present current,

factual and balanced information. Discussions focus on the etiology,

signalment, clinical signs, laboratory findings, diagnosis, medical/surgical

treatment options, cutting-edge therapies (e.g. Dermatonin implant,

stereotactic radiation, hypophysectomy) and long-term management of Cushings

(typical, atypical, iatrogenic) in dogs and cats.

Other topics include evidence- and science-based CAVM, the role of

lifestyle, genetic and environmental risk factors, vaccination, therapeutic

nutrition, homemade diets, physiology, physical therapy, financial aid and

hospice care. Scientific papers, conference proceedings, journal articles

and endocrine disease in other species are also discus


Greater Monroe Kennelgreatermonroekc.org/files/August_2014_Newsletter.pdfGreater Monroe Kennel...

Documents

Transcript of Greater Monroe Kennelgreatermonroekc.org/files/August_2014_Newsletter.pdfGreater Monroe Kennel...